The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series

Journal of Psychopharmacology
Se Hyun Kim Yong Sik Kim

Abstract

Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 +/- 33.1 and 4.2 +/- 4.2 days/year, respectively. Participants also showed great improvements in social skills. These f...Continue Reading

References

Nov 1, 1995·The American Journal of Psychiatry·A R KoreenT B Cooper
Sep 1, 1995·The American Journal of Psychiatry·S C TysonS C Risch
May 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·D MarinkovicV R Paunovic
Dec 1, 1993·The American Journal of Psychiatry·M Burke, C S Sebastian
Jun 9, 1999·The American Journal of Psychiatry·R R ConleyJ J Bartko
Jun 14, 2000·The Annals of Pharmacotherapy·L Davydov, S R Botts
Jun 2, 2001·Journal of Clinical Psychopharmacology·I GaertnerK Dietz
Dec 17, 2002·European Journal of Clinical Pharmacology·K RaaskaP J Neuvonen
Jun 5, 2003·The American Journal of Psychiatry·John M KaneKeith Karcher
Jul 13, 2004·Schizophrenia Research·Mariëlle EerdekensErik Mannaert
Dec 31, 2004·The American Journal of Psychiatry·Richard C JosiassenRita A Shaughnessy
Apr 5, 2005·The International Journal of Neuropsychopharmacology·Robert A LasserRoss J Baldessarini
Apr 7, 2005·International Clinical Psychopharmacology·Yong Min AhnYong Sik Kim
Sep 21, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Vassilis P KontaxakisDimitris K Roukas
Jan 18, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Josep Maria HaroPeter B Jones
Feb 3, 2006·The New England Journal of Medicine·William G HonerUNKNOWN Clozapine and Risperidone Enhancement (CARE) Study Group
Aug 31, 2006·The International Journal of Neuropsychopharmacology·David M TaylorMaxine X Patel
Oct 31, 2006·Schizophrenia Research·Christoph U CorrellPeter Manu
Jan 30, 2007·Current Medical Research and Opinion·Sandra L TunisBruce J Kinon
May 17, 2007·Current Drug Metabolism·Manoranjenni Chetty, Michael Murray
Jun 15, 2007·The Australian and New Zealand Journal of Psychiatry·Srinivasan Tirupati, Ling-Ern Chua
Nov 21, 2007·The British Journal of Psychiatry. Supplement·Samantha Hamer, Peter M Haddad
Mar 1, 2008·Journal of Psychopharmacology·M TaylorKate Peperell
Apr 26, 2008·Schizophrenia Bulletin·Corrado BarbuiAndrea Cipriani
Oct 9, 2008·Clinical Therapeutics·Sofie A M K HouthoofdBernard G C Sabbe
Oct 25, 2008·Joint Commission Journal on Quality and Patient Safety·Jessica L GörenRichard C Hermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here